Human PilotPubMed ID: 35689754·2022

Tirzepatide Reduces Blood Pressure in Hypertensive Obesity

Garvey WT, Frias JP, Dickinson S, et al.

American Journal of Hypertension, 2022 · n = 352

Key finding

Tirzepatide 15mg reduced systolic BP by 12.8 mmHg versus 4.2mmHg placebo (p<0.001); 47% reduced antihypertensive medications.

Summary

Exploratory analysis showing tirzepatide-induced weight loss produced significant blood pressure reductions.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot